mesna / Generic mfg. - LARVOL DELTA

Primary Biphasic Synovial Sarcoma of the Stomach Presenting With Spontaneous Hemorrhage: A Case of a Rare Gastric Neoplasm (ACG 2026) - "Adjuvant AIM chemotherapy (doxorubicin, ifosfamide, mesna) was initiated, with four of five planned cycles completed. This case highlights the importance of molecular diagnostics in rare gastric mesenchymal neoplasms. Figure: Figure 1A: MRI (size of hemorrhagic mass) / Figure 1B: CT (mass with hemoperitoneum) Figure: Figure 2: Macroscopic anatomy of gastric mass"

Clinical • Gastric Cancer • Gastrointestinal Stromal Tumor • Hematological Disorders • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • CA 19-9 • CD99 • MUC16 • SS18

Massive Retroperitoneal Liposarcoma Presenting as Malignant Gastrointestinal Obstruction Without Classic Radiographic Small Bowel Obstruction (ACG 2026) - "The patient was managed conservatively with liquid diet, bladder decompression, nutritional optimization, symptom control, and evaluation for systemic chemotherapy with doxorubicin/ifosfamide/mesna (AIM regimen). Marked visceral compression and bowel displacement from extensive tumor burden can result in clinically significant malignant gastrointestinal obstruction without classic imaging findings. Clinicians should recognize that progressive mass effect alone may produce obstructive physiology, even when radiographic findings appear discordant with symptom severity."

Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Liposarcoma • Retroperitoneal Sarcoma • Sarcoma • Solid Tumor

A Fatal Masquerade: Acute Liver Failure as the Initial Presentation of Adult T-Cell Leukemia/Lymphoma (ACG 2026) - "He received N-acetylcysteine for ALF as active malignancy precluded him from liver transplant eligibility. Treatment for ATLL included dexamethasone and hyperfractionated cyclophosphamide with mesna, followed by vincristine and doxorubicin...Figure: Trend of patient's liver function tests, white blood cell count, platelet count, and atypical lymphocytes throughout the course of his hospitalization Figure: Peripheral smear with characteristic flower cell: Atypical lymphocyte with condensed chromatin and deeply lobulated, cloverleaf-like nuclei also known as a âflower cellâ (black arrow) as seen in carriers of the HTLV-1 virus. High power (100x) microscopy with oil immersion"

Clinical • Adult T-Cell Leukemia-Lymphoma • CNS Disorders • Gastroenterology • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. (PubMed, Lancet Haematol) - P1/2 | "Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Cardiovascular • Diabetes • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial (ASH 2021) - P2 | "The regimen consisted of 21 day cycles of PEM 200 mg IV on day 1 with standard ICE including ifosfamide 5 g/m2 with MESNA as a 24hr continuous infusion on day 2, carboplatin AUC 5 IV (max 800 mg) on day 2, and etoposide 100 mg/m2/day IV on days 1 to 3. Pembrolizumab with ICE chemotherapy is a tolerable and efficacious regimen with high CMR rate as assessed by PET/CT. Despite short follow up, patients had excellent PFS and OS in the post-transplant setting. The results support further investigation of PEM-ICE as second-line treatment for AHSCT eligible patients with relapsed and refractory classical Hodgkin lymphoma."

Clinical • P2 data • Acute Respiratory Distress Syndrome • Anemia • Back Pain • Bone Marrow Transplantation • Cardiovascular • Fatigue • Heart Failure • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Musculoskeletal Pain • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Transplantation

Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases. (PubMed, Clin Nucl Med) - "A 23-year-old man with metastatic extraskeletal Ewing sarcoma, who was unable to tolerate standard-dose chemotherapy, received 1 cycle of 177Lu-FAP-2286, followed by 2 cycles of reduced-dose ifosfamide/epirubicin/mesna chemotherapy. The patient remained symptom-free at 2 months. This case suggests that 177Lu-FAP-2286 combined with chemotherapy may have clinical utility in advanced Ewing sarcoma."

Journal • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov) - P2 | N=41 | Recruiting | Sponsor: St. Jude Children's Research Hospital | Initiation date: Jun 2026 ➔ Sep 2026

Trial initiation date • Lung Cancer • Oncology • Osteosarcoma • Pediatrics • Sarcoma • Solid Tumor

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up (ASH 2024) - P1/2 | "Treatment included Bv on Days 1 and 8 at either 1.2 or 1.5 mg/kg (based on 3+3 dose-escalation schema; capped at 150 mg), ifosfamide and mesna 5 g/m2 each on Day 2, carboplatin AUC 5 (capped at 800 mg) on Day 2, and etoposide 100 mg/m2 daily on Days 1-3. Overall, five pts have died since enrollment on the study due to second cancers (3), study treatment (1), or complications of ASCT (1). Conclusions : As the field of CHL shifts to incorporate PD1-inhibitors in the front-line setting, the Bv-ICE regimen may provide primary refractory patients an effective salvage treatment option."

Clinical • Basal Cell Carcinoma • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lung Adenocarcinoma • Lung Cancer • Lymphoma • Melanoma • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • TNFRSF8

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov) - P1 | N=6 | Terminated | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Terminated; Polaris decided to close to accrual.

Trial termination • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

A narrative review of emerging chemoprotective agents for chemotherapy-induced toxicity: nanoformulated natural products, dual COX-2/TNF-α inhibitors, and Nrf2 modulators. (PubMed, Front Pharmacol) - "Established chemoprotective agents (dexrazoxane, mesna, and amifostine) are limited by narrow indications (dexrazoxane: only anthracycline cardiotoxicity), significant adverse effects (amifostine: hypotension in 62%), and lack of efficacy against common toxicities such as peripheral neuropathy...Three major emerging categories were identified: (i) Nanoformulated natural products such as curcumin, resveratrol, luteolin, and naringenin encapsulated in polymeric, lipid, or cyclodextrin-based nanocarriers, demonstrate improved bioavailability and enhanced efficacy in preclinical models though chemoprotection-specific clinical data remain limited (ii) Dual COX-2/TNF-α inhibitors (e.g., NO-donating aspirin)...Physical strategies (limb hypothermia) and repurposed drugs (metformin) offer additional avenues but need Phase III validation...Future trials must incorporate biomarker-driven enrollment and standardized chemoprotection endpoints. Comparative analysis across categories..."

Journal • Review • Cardiovascular • Genetic Disorders • Hypotension • Oncology • Pain • CTNNB1 • STAT3

Small Molecule Thiol Self-Assembled Interlayer Enhances Carrier Extraction at CZTSSe/CdS Interface for High Efficiency Photovoltaics. (PubMed, ACS Appl Mater Interfaces) - "By comparing thiol molecules bearing hydroxyl, carboxyl, amino, and sulfonic acid terminal groups, sodium 2-mercaptoethanesulfonate (Mesna) is identified as the most effective interfacial modifier...As a result, the power conversion efficiency is improved from 11.50% to 12.93%. This work demonstrates that thiol-SAI-assisted interface engineering provides an effective strategy for coordinating buffer-layer growth with heterojunction quality, offering a general molecular-level approach for optimizing charge extraction in solution-processed thin-film solar cells."

Journal

Effects of perioperative MESNA on lipid peroxidation and myocardial injury in patients undergoing coronary artery bypass grafting: a randomized, double-blind, placebo-controlled trial. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In patients undergoing elective on-pump CABG, perioperative administration of MESNA was associated with reduced postoperative lipid peroxidation, lower CK-MB release, and improved early postoperative ventricular function. Larger multicenter studies are needed to confirm these findings and their clinical significance."

Clinical • Journal • Cardiovascular • Reperfusion Injury • TNNI3

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis (clinicaltrials.gov) - P2 | N=8 | Recruiting | Sponsor: Paul Szabolcs | Trial completion date: Aug 2026 ➔ Aug 2028 | Trial primary completion date: Aug 2026 ➔ Aug 2028

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Transplantation

Primary pulmonary artery synovial sarcoma: a case report. (PubMed, AME Case Rep) - "Six months post-surgery, imaging revealed local recurrence and lung metastases, and the patient received two cycles of ifosfamide, pirarubicin, and mesna chemotherapy with good tolerance. A broad base, unclear border, and atypical contrast perfusion should raise suspicion for malignancy. Definitive diagnosis relies on histopathology and molecular detection of SS18 rearrangement."

Journal • Cardiovascular • Oncology • Pain • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • SS18

A Study of N9 Chemotherapy in Children With Neuroblastoma (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • MYCN

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=24 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=129 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial primary completion date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report. (PubMed, Front Oncol) - "Due to borderline pulmonary function, she was initially deemed a poor surgical candidate and referred to a sarcoma specialty center, where neoadjuvant chemotherapy with Adriamycin, Ifosfamide, and Mesna was initiated locally. This case highlights the aggressive clinical course of PPSS despite optimal multimodal therapy including neoadjuvant chemotherapy and complete surgical resection. Recurrence and metastasis remain common even following apparent initial response to therapy, underscoring the need for improved targeted systemic therapies and broader access to clinical trials for this rare malignancy."

Journal • Lung Cancer • Oncology • Palliative care • Respiratory Diseases • Sarcoma • Solid Tumor • Synovial Sarcoma • Tobacco Cessation • SSX1

Adult Undifferentiated Embryonal Sarcoma of the Liver with Spontaneous Tumor Rupture and Comprehensive Molecular Profiling: A Case Report. (PubMed, Case Rep Oncol) - "The patient received five cycles of adjuvant doxorubicin, ifosfamide, and mesna, which were discontinued due to cumulative chemotherapy-induced anemia and fatigue. This case highlights the prognostic significance of spontaneous tumor rupture and demonstrates that molecular profiling can identify biologically relevant alterations - including MAGE-A4 expression - that could inform future investigational approaches. Collaborative multi-institutional efforts are needed to establish standardized treatment protocols for this rare malignancy."

Journal • Tumor mutational burden • Chemotherapy-Induced Anemia • Fatigue • Hematological Disorders • Hepatology • Liver Cancer • Oncology • Pain • Sarcoma • Solid Tumor • CDKN2B • HLA-A • MAGEA4 • TMB

HAP2HCT: TCR??-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov) - P2 | N=69 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Jun 2026 ➔ Dec 2027

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Juvenile Myelomonocytic Leukemia • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • AFDN • CBFA2T3 • CREBBP • DEK • ETV6 • FLT3 • GLIS2 • HOXA9 • KAT6A • KDM5A • KMT2A • MLLT10 • NSD1 • NUP214 • NUP98 • RUNX1 • WT1

PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - P1/2 | N=12 | Active, not recruiting | Sponsor: Ossium Health, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2027 ➔ May 2029

Enrollment closed • First-in-human • Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • HLA-B • HLA-C • HLA-DRB1

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study. (PubMed, BMC Med) - P=N/A | "The Lipo-MIT-based R-MINE-containing regimen showed encouraging efficacy and a manageable safety profile in R/R DLBCL, warranting further validation."

Journal • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting. (PubMed, JCO Oncol Pract) - "These findings demonstrate that ifosfamide-based regimens through a structured outpatient model are both safe and reducing hospital resource utilization while maintaining treatment adherence and patient safety."

Journal • Hematological Disorders • Oncology • Sarcoma • Solid Tumor

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors (clinicaltrials.gov) - P2 | N=92 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Germ Cell Tumors • Lung Cancer • Oncology • Testicular Cancer • AFP

Limited, low-certainty evidence for pharmacological treatments used alone or adjunctively in painful intra-articular temporomandibular disorders: a systematic review and network meta-analysis. (PubMed, Odontology) - "In TMJ-DDs, multiple interventions demonstrated statistically significant short-term (≤ 3 months) pain reductions, with only MESNA (sodium 2-mercaptoethanesulfonate) and arthrocentesis with hyaluronic acid (HA) also showing statistically significant effects in the long-term (> 3 months)...Overall, the evidence indicates limited and inconsistent clinical benefits, and no available treatment can be recommended with confidence. This study highlights the urgent need for additional high-quality RCTs to generate robust and clinically meaningful evidence to guide practice in painful iTMDs."

Clinical • Journal • Retrospective data • Review • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology